Compare Eli Lilly And Co (LLY) vs iShares TIPS Bond ETF (TIP) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

TIP trades at $108.05, down 0.2% today, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The stock lacks disclosed valuation metrics like P/E and P/S, and recent news highlights bond market volatility and Federal Reserve uncertainty influencing investor sentiment. Dividend payments are scheduled for 2026, providing income visibility.

Outlook is cautious due to bearish technical signals and macroeconomic risks from potential Fed rate hikes. Investment opportunities include dividend income, but risks involve market volatility and lack of current fundamental data. Investors should await earnings reports for clarity on financial health.